Nhà máy Stada
Stada
stada
stada
Antifungals & Antivirals

Lamzidivir

 

Pack szie:

Box of 5 blisters x 6 film-coated tablets.

 

Composition:

Each film-coated tablet contains lamivudine 150mg and zidovudine 300mg.

 

Shelf-life:

48 months from the date of manufacturing.

Store in a well-closed container, in a dry place. Do not store above 30oC.

 

  • Indications and Dosage & Administration
  • Contraindications
  • Adverse reactions
  • Precautions

  • Lamzidivir in combination with other antiretroviral agents is indicated for the treatment of HIV infection.
     
  • Lamzidivir is orally taken. 
     
  • Adults and adolescents (at least 12 years of age):
    The recommended oral dose of Lamzidivir is 1 tablet (containing 150 mg of lamivudine and 300 mg of zidovudine) twice daily. 
     
  • Dose adjustment:
    Because it is a fixed-dose combination, Lamzidivir should not be prescribed for patients requiring dosage adjustment such as those with reduced renal function (creatinine clearance < 50 ml/min) or those experiencing dose-limiting adverse events; patients with impaired hepatic function.

 

Or as prescribed by physicians.

 

  • Lamzidivir is contraindicated in patients with previously demonstrated clinically significant hypersensitivity to any ingredient of the drug.

     

  • Redistribution/accumulation of body fat
  • Cardiomyopathy.
  •  Gynecomastia, hyperglycemia.
  • Oral mucosal pigmentation, stomatitis.
  • Vasculitis, weakness.
  • Anemia, (including pure red cell aplasia and anemias progressing on therapy), lymphadenopathy, splenomegaly.
  • Lactic acidosis and hepatic steatosis, pancreatitis, posttreatment exacerbation of hepatitis B.
  • Sensitization reactions (including anaphylaxis), urticaria.
  • Muscle weakness, CPK elevation, rhabdomyolysis.
  • Paresthesia, peripheral neuropathy, seizures.
  • Abnormal breath sounds/wheezing.
  • Alopecia, erythema multiforme, Stevens-Johnson syndrome.

     

  • Zidovudine has been associated with hematologic toxicity including neutropenia and severe anemia, particularly in patients with advanced HIV disease. Prolonged use of zidovudine has been associated with symptomatic myopathy. Lamzidivir should be used with caution in patients who have bone marrow compromise evidenced by granulocyte count < 1,000 cells/mm3 or hemoglobin < 9.5 g/dl.
  • Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including lamivudine, zidovudine, and other antiretrovirals.
  • Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and HIV and have discontinued lamivudine. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue Lamzidivir and are co-infected with HIV and HBV.
  • Patients with impaired renal function: Patients with creatinine clearance < 50 ml/min should not receive Lamzidivir.
  • Pediatric use: Lamzidivir should not be administered to pediatric patients less than 12 years of age because it is a fixed-dose combination that cannot be adjusted for this patient population.
  • Geriatric use: Dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
  • Pregnancy: There are no adequate and well-controlled studies of Lamzidivir in pregnant women. Lamzidivir should be used during pregnancy only if the potential benefits outweigh the risks.
  • Lactation: Because of both the potential for HIV transmission and the potential for serious adverse reactions in nursing infants, mothers should be instructed not to breastfeed if they are receiving Lamzidivir.
  • Effects on ability to drive and use machines: Unknown data.

     

Contact us

FACTORY 1: K63/1 Nguyen Thi Soc St., Xuan Thoi Dong, Hoc Mon, HCMC
Tel: +84 28 3718 2141 - Fax: +84 28 3718 2140

FACTORY 2: 40 Tu Do Avenue, VietNam-Singapore Industrial Park, Binh Duong
Tel: +84 274 376 7470 - Fax: +84 274 376 7469
Email : stada@stada.com.vn
Website: www.stada.com.vn



Visitors Counter

Online
39
Total